News Releases Year None20202019201820172016 BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors 02.24.2020 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences 02.21.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 02.05.2020 BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source 01.13.2020 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity 01.10.2020 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma 01.08.2020 BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma 01.06.2020
